retatrutide safety trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 VisualAbstract: Retatrutide reduces body weight

It is important to note that whilst these findings are promising, there is no official consensus on GLP-1 receptor agonists being prescribed specifically as anti-inflammatory agents

Retatrutide (CAS 2381089-83-2) is employed across a range of in vitro and preclinical research contexts focused on metabolic receptor biology, energy homeostasis signaling, and multi-receptor pharmacology

The FDA requires accurate labeling, good manufacturing practices (GMP), and truthful marketing claims

The impact of amino acids on postprandial glucose and insulin kinetics in humans: a quantitative overview

Macrophages have a pivotal role in the disease process, by both initiating and maintaining an inflammatory state [9,10,11,12,13]